Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study
Berna Demiralp,1 Lane Koenig,1 Jaya Kala,2 Chaoling Feng,1 Elizabeth G Hamlett,1 Marie Steele-Adjognon,1 Suzanne Ward3 1KNG Health Consulting, Rockville, MD, USA; 2University of Texas Health Science Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3BTG International, West Con...
Saved in:
Main Authors: | Demiralp B (Author), Koenig L (Author), Kala J (Author), Feng C (Author), Hamlett EG (Author), Steele-Adjognon M (Author), Ward S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis
by: Kala J, et al.
Published: (2023) -
Care fragmentation and readmission mortality and length of stay before and during the COVID-19 pandemic: data from the National Readmissions Database, 2018-2020
by: Sara Turbow, et al.
Published: (2024) -
Glucarpidase to combat toxic levels of methotrexate in patients
by: Green JM
Published: (2012) -
Decreasing length of maternal hospital stay is not associated with increased readmission rates
by: Jane B. Ford, et al.
Published: (2012) -
Impact of gaps in care for malnourished patients on length of stay and hospital readmission
by: Joanna Bryan Ringel, et al.
Published: (2019)